Histo-Epidemiological Profile of Endometrial Cancer in the Oran Region

  • Anissa FIZAZI Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria
  • Imene BOUZOUINA Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria
  • Assala Nesrine BOUZIANI Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria
  • Amina BELHADJ Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria
  • Sonia SEDDIKI Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria
  • Tewfik SAHRAOUI Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Abstract

Objective: The aim of the present study is to describe the epidemiological, histopathological and therapeutic profile of endometrial cancers in the region of Oran.


Methods: We conducted a retrospective study by exploring the medical files of 25 female patients diagnosed of endometrial cancer and treated at the level of the EHU November 1, 1954’s medical oncology department in Oran during the period from January 2015 to December 2019.


For data collection, we used a structured exploitation sheet to obtain necessary information. Variables were analyzed using SPSS Software Version 20.0.


Results: The median age of patients was 59 years with extremes ranging from 42 to 83 years. More than 56% of our patients were over 50 years old, 40% of the patients were nulliparous and 80% postmenopausal. The average age of menarche was 14.09 ± 1.44 years with extremes ranging from 12 to 17 years. The indication for anatomopathological examination was dominated by metrorrhagia (80%).


Histopathologically, endometrioid adenocarcinoma was the most common at 75% of cases. We also note that 62.5% were classified in stage I and 37.5% in stage II. Myometrium infiltration was observed in 66.67% of cases. The basic treatment for endometrial cancer remains surgical.


Conclusion: At the end of this work, we concluded that this pathology remains essentially that of postmenopausal women. Endometrioid adenocarcinoma was the most common histologic type. This study also revealed many risk factors for endometrial cancer, such as advanced age, hypertension and nulliparity.


Keywords: Cancer, Endometrium, Epidemiology, Anathomopathology, Risk factors

Keywords: Cancer, Endometrium, Epidemiology, Anathomopathology, Risk factors

Downloads

Download data is not yet available.

Author Biographies

Anissa FIZAZI, Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Imene BOUZOUINA, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Assala Nesrine BOUZIANI, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Amina BELHADJ, Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Sonia SEDDIKI, Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Tewfik SAHRAOUI, Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

Biology of Development and Differentiation Laboratory, Department of Biology, Faculty of Natural and Life Sciences, University of Oran1, Ahmed Ben Bella, Algeria

References

1- Ferlay J , Colombet M , Soerjomataram I , Mathers C , Parkin D M , Piñeros M et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer . 2019; 144 (8):1941-1953.
2- Pomel C , Perbet E, Dauplat J, Martinez A, Canis M, Philippe A C et al. Le curage lombo-aortique en question (s)… Gynécologie Obstétrique & Fertilité. 2013; 5 (41):273-274.
3- Lyoke CA, Ugwu GO. Burden of gynaecological cancers in developing countries. World J Obstet Gynecol. 2013; 2(1):1–7 5.
4- Sancho-Garnier H. Epidémiologie des cancers gynécologiques : utérus, ovaire, vulve, vagin. In: Riethmuller D, Carcopino X (eds) Cancers gynécologiques pelviens. Elsevier Masson, Paris, 2013; 85-99 8.
5- Sénéchal C, Cottereau E, de Pauw A, et al . Les facteurs de risque génétiques et environnementaux des cancers de l’endomètre. Bull Cancer. 2013; 102 (3):256–69
6- Peignaux K, Truc G, Blanchard N, Créhange G, Maingon P. Cancer de l’endomètre de stade I. Cancer/Radiothérapie . 2008; 12( 6-7):625-629.
7- Buhler J, Routiot T, Polet-Lefebvre K, Morel O. Évaluation de l’échographie et de l’IRM dans la stadification des tumeurs de l’endomètre de stage I. Gynécologie Obstétrique & Fertilité . 2015; 43(4):329-331.
8- Doghri R, Yahyaoui Y, Gabsi A, Driss M, Boujelbenea N, Charfia L. Les carcinomes de l’endomètre: étude anatomopathologique et histopronostique à propos de 62 cas dans un centre du Nord tunisien. Annales de Pathologie. Elsevier Masson, 2018 : 85-91.
9- Sando Z, Fouogue J T, Fouelifack F Y, Fouedjio J H, Mboudou E T, Essame JL. Profil des cancers gynécologiques et mammaires à Yaoundé-Cameroun. Pan African Medical Journal. 2014; 17 (1).
10- Parsonsa L H P , Pedersenb R, Richardsona D L, Khoc K L. The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018; 223:108-112.
11- Ouédraogo A S, Sanou-Lamien A M, Ouédraogo-Tiendrébéogo R, Ramde N, Konsegre V, Ido F, Goumbri-Lompo O M, Soudre B R. Aspects histoépidémiologiques du cancer de l’endomètre à Ouagadougou.. Journal Africain du Cancer/African Journal of Cancer. 2011; 3(4):251-255.
12- De Kerdaniel O, Bodya N, Davoinea E , Foucher F, Henno S, Tavenardc A. et al. Application des recommandations dans la prise en charge du cancer de l’endomètre en pratique clinique. Étude rétrospective bretonne. Journal de Gynécologie Obstétrique et Biologie de la Reproduction. 2016; 45(9):1045-1053.
13- Koual M, Ngo C, Girault A, Le´curu F, Bats A. Endometrial cancer in the elderly: does age influence surgical treatments, outcomes, and prognosis?. Menopause. 2018; 25( 9):968-976.
14- Loaec C, Vaucel E, Darnis E, Lopes P, Selmes G, Jaffre I et al. Clinical practice for morbidly obese endometrial cancer patients: A french multicentric study. Bulletin du cancer. 2018 ; 105(5):441-449.
15- Yazbeck C, Dhainaut C, Thoury A, Driguez P, Madelenat P. Conservative treatment of endometrial cancer and atypical hyperplasia. Gynecologie, Obstetrique & Fertilite. 2004; 32(5):433-441.
16- Reis N, Beji N K. Risk factors for endometrial cancer in Turkish women: results from a hospital-based case–control study. European Journal of Oncology Nursing. 2009; 13(2):122-127.
17- Rice L W. Hormone prevention strategies for breast, endometrial and ovarian cancers. Gynecologic Oncology . 2010; 118(2):202-207.
18- Fujita M, Tase T, Kakugawa Y, Hoshi S, Nishino Y, Nagase S et al. Smoking, earlier menarche and low parity as independent risk factors for gynecologic cancers in Japanese: a case-control study. The Tohoku journal of experimental medicine. 2008; 216(4):297-307.
19- Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, Linkov F. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851-6.
20- Engbang N J P, Essome H, Tchente N C, Essam S J D, Elono F A M, Ateba G R et al. Cancer de l’endomètre au Cameroun : profil histo-épidémiologique de 176 cas. Journal Africain du Cancer/African Journal of Cancer. 2015; 7, (4):218-222.
21- MALIK, Tahira Y., et al. Comparison of risk factors and survival of type 1 and type II endometrial cancers. Pakistan journal of medical sciences. 2016; 32(4):886.
22- Münstedt K, Grant P, Woenckhaus J, Roth G, Tinneberg H. Cancer of the endometrium: current aspects of diagnostics and treatment. World journal of surgical oncology. 2004; 2(1):1-17.
23- Boruta DM, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecologic oncology. 2009; 115( 1):142-153.
24- Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Treatment modalities in endometrial cancer. Current opinion in oncology. 2007; 19(5):479-485.
25- Win A, Reece J C, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstetrics & Gynecology. 2015; 125(1):89-98.
26- Seger H M, Seger H M, Soisson A P, Dodson M K, Rowe K G, Cannon-Albright L A, et al. Familial clustering of endometrial cancer in a well-defined population. Gynecologic oncology. 2011; 122(1):75-78.
27- Bharati R, Jenkins M, Lindor N , Marchand L, Gallinger S, Haile R, Newcomb P, Hopper J. Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer?. Gynecologic oncology. 2014; 133(2):287-292.
28- Rossard L, Rua C, Duquesne M , Vildé A, Marret H, Body G, et al. Reliability of imaging modalities for preoperative assessment of patients with endometrial carcinoma. Gynecologie, Obstetrique & Fertilite. 2013; 41(11):641-647.
29- Nouni K, Diakité A, Masbah W, Kebdani T, Hassouni K, Benjaafer N, et al. Traitements adjuvants et rôle de la radiothérapie dans le cancer de l’endomètre. Cancer/ Radiothérapie. 2010; 6(14):656.
30- Gull B, Karlsson B, Milsom I, Granberg S. Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endom etrium as predictors of endometrial cancer. American journal of obstetrics and gynecology. 2003; 188(2):401-408.
31- Dueholm M, Forman A, Jensen M L, Laursen H, Kracht P. Transvaginal sonography combined with saline contrast sonohysterography in evaluating the uterine cavity in premenopausal patients with abnormal uterine bleeding. Ultrasound in Obstetrics and Gynecology: the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology.2001; 18(1):54-61.
32- Bazot M., Bendavid S, Robert Y. Place de l’échographie doppler et de l’IRM pour le diagnostic et le bilan d’extension des cancers de l’endomètre. La Lettre du gynécologue. 2002, 274:24-26.
33- Engbang N J P, Essome H, Tchente N C, Essam S J D, Elono F A M, Ateba G R et al. Cancer de l’endomètre au Cameroun : profil histo-épidémiologique de 176 cas. Journal Africain du Cancer/African Journal of Cancer [en ligne]. 2015; 7(40):218-222.
34- N’Dah K J, Doukoure B, Troh E, Aman N A, Koffi K E, Kouamé A D, et al. Epidemiological and Histological Aspects of Women Genital Cancers in Côte d’Ivoire. Open Journal of Obstetrics and Gynecology
35- Sando Z, Fouogue J T, Fouelifack F Y, Fouedjio J H, Mboudou E T, Essame JL. Profil des cancers gynécologiques et mammaires à Yaoundé-Cameroun. Pan African Medical Journal[en ligne]. 2014 ; 17:1.
36- Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2013; 24(suppl 6):VI33-VI38.
37- Brémond A, Bataillard A, Thomas L, Achard J L, Fervers B, Fondrinier E, Lansac J, Bailly C, Hoffstetter S, Basuyau J P, d'Anjou J, Descamps P, Farsi F, Guastalla J P, Laffargue F, Rodier JF, Vincent P, Pigneux J.Br J Cancer. 2001; 84(Suppl 2):31–36.
38- Uzan C, Gouy S, Pautier P, Lhommé C, Duvillard P, Haie-Meder C, et al. French recommendations for endometrial cancer 2010: clinical use and questions still debated. Bulletin du cancer. 2012 ; 99(1):107.
39- Despierre E, Moerman P, Vergote I, Amant. Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?. International Journal of Gynecologic Cancer. 2006 ; 16(Suppl 1):273-277.
40- Gücer F, Yilmaz O, Balkanli-Kaplan P, Ali Yüce M. Complete remission of an endometrial carcinoma with bilateral multiple pulmonary and extrapelvic metastases treated by surgery and chemotherapy consisting of paclitaxel and carboplatin. International Journal of Gynecologic Cancer. 2005; 15(6).
Statistics
0 Views | 0 Downloads
How to Cite
1.
FIZAZI A, BOUZOUINA I, BOUZIANI AN, BELHADJ A, SEDDIKI S, SAHRAOUI T. Histo-Epidemiological Profile of Endometrial Cancer in the Oran Region. JDDT [Internet]. 15Oct.2020 [cited 21Oct.2020];10(5-s):143-8. Available from: http://jddtonline.info/index.php/jddt/article/view/4354